Does the media favor MDGL or VKTX?

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than Viking Therapeutics. MarketBeat recorded 17 mentions for Madrigal Pharmaceuticals and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Madrigal Pharmaceuticals' score of 0.54 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LLY or VKTX?

In the previous week, Eli Lilly and Company had 121 more articles in the media than Viking Therapeutics. MarketBeat recorded 135 mentions for Eli Lilly and Company and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Eli Lilly and Company's score of 0.65 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 58 Very Positive mention(s) 35 Positive mention(s) 22 Neutral mention(s) 13 Negative mention(s) 5 Very Negative mention(s) Positive Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VKTX or PFE?

In the previous week, Pfizer had 37 more articles in the media than Viking Therapeutics. MarketBeat recorded 51 mentions for Pfizer and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Pfizer's score of 0.40 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pfizer 19 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 10 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SMMT or VKTX?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.07 N/A Viking Therapeutics N/A N/A -$359.64M -$5.40 N/A

Is SMMT or VKTX more profitable?

Viking Therapeutics' return on equity of -117.35% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -138.82% -117.11% Viking Therapeutics N/A -117.35% -88.87%

Does the media prefer SMMT or VKTX?

In the previous week, Summit Therapeutics had 3 more articles in the media than Viking Therapeutics. MarketBeat recorded 17 mentions for Summit Therapeutics and 14 mentions for Viking Therapeutics. Summit Therapeutics' average media sentiment score of 0.95 beat Viking Therapeutics' score of 0.86 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VKTX or HALO?

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Viking Therapeutics. MarketBeat recorded 16 mentions for Halozyme Therapeutics and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Halozyme Therapeutics' score of 0.24 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Viking Therapeutics (VKTX) Competitors

$29.22 +1.64 (+5.95%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$29.17 -0.05 (-0.16%)

As of 11/13/2026 07:59 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, SMMT, and HALO

Should you buy Viking Therapeutics stock or one of its competitors? Viking Therapeutics's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), Summit Therapeutics (SMMT), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Madrigal Pharmaceuticals has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.43B	6.95	-$288.28M	-$5.98	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A

In the previous week, Madrigal Pharmaceuticals had 3 more articles in the media than Viking Therapeutics. MarketBeat recorded 17 mentions for Madrigal Pharmaceuticals and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Madrigal Pharmaceuticals' score of 0.54 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -10.89%. Madrigal Pharmaceuticals' return on equity of -27.08% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-10.89%	-27.08%	-12.04%
Viking Therapeutics	N/A	-117.35%	-88.87%

Madrigal Pharmaceuticals presently has a consensus price target of $706.87, indicating a potential upside of 65.39%. Viking Therapeutics has a consensus price target of $93.36, indicating a potential upside of 219.52%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Madrigal Pharmaceuticals and Viking Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Eli Lilly and Company has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eli Lilly and Company has a net margin of 31.90% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 86.76% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	31.90%	86.76%	22.03%
Viking Therapeutics	N/A	-117.35%	-88.87%

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	20.84	$20.64B	$30.81	46.87
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A

In the previous week, Eli Lilly and Company had 121 more articles in the media than Viking Therapeutics. MarketBeat recorded 135 mentions for Eli Lilly and Company and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Eli Lilly and Company's score of 0.65 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	58 Very Positive mention(s)	35 Positive mention(s)	22 Neutral mention(s)	13 Negative mention(s)	5 Very Negative mention(s)	Positive
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eli Lilly and Company currently has a consensus target price of $1,416.64, indicating a potential downside of 1.90%. Viking Therapeutics has a consensus target price of $93.36, indicating a potential upside of 219.52%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Eli Lilly and Company beats Viking Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Viking Therapeutics (NASDAQ:VKTX) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Pfizer has a net margin of 6.34% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.88% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-117.35%	-88.87%
Pfizer	6.34%	19.88%	8.52%

Viking Therapeutics currently has a consensus price target of $93.36, suggesting a potential upside of 219.52%. Pfizer has a consensus price target of $30.32, suggesting a potential upside of 4.95%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Pfizer	2 Sell rating(s)	14 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.18

Viking Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Pfizer had 37 more articles in the media than Viking Therapeutics. MarketBeat recorded 51 mentions for Pfizer and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Pfizer's score of 0.40 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	19 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	10 Negative mention(s)	3 Very Negative mention(s)	Neutral

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A
Pfizer	$62.58B	2.63	$7.77B	$0.70	41.27

Summary

Viking Therapeutics and Pfizer tied by winning 8 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

In the previous week, Summit Therapeutics had 3 more articles in the media than Viking Therapeutics. MarketBeat recorded 17 mentions for Summit Therapeutics and 14 mentions for Viking Therapeutics. Summit Therapeutics' average media sentiment score of 0.95 beat Viking Therapeutics' score of 0.86 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.07	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A

Summit Therapeutics presently has a consensus target price of $28.61, suggesting a potential upside of 102.17%. Viking Therapeutics has a consensus target price of $93.36, suggesting a potential upside of 219.52%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summit Therapeutics has a beta of -1.49, suggesting that its stock price is 249% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Viking Therapeutics' return on equity of -117.35% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-138.82%	-117.11%
Viking Therapeutics	N/A	-117.35%	-88.87%

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Viking Therapeutics beats Summit Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Viking Therapeutics compare to Halozyme Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Viking Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A
Halozyme Therapeutics	$1.40B	8.19	$316.89M	$3.93	25.51

Halozyme Therapeutics has a net margin of 26.93% compared to Viking Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-117.35%	-88.87%
Halozyme Therapeutics	26.93%	751.81%	23.84%

In the previous week, Halozyme Therapeutics had 2 more articles in the media than Viking Therapeutics. MarketBeat recorded 16 mentions for Halozyme Therapeutics and 14 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.86 beat Halozyme Therapeutics' score of 0.24 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics currently has a consensus price target of $93.36, suggesting a potential upside of 219.52%. Halozyme Therapeutics has a consensus price target of $108.18, suggesting a potential upside of 7.89%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Halozyme Therapeutics	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Halozyme Therapeutics beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.52B	$4.12B	$7.84B	$12.19B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	-5.41	25.73	34.71	28.44
Price / Sales	N/A	16.57	8.66	5.84
Price / Cash	N/A	26.37	21.93	22.49
Price / Book	6.32	4.00	4.35	3.76
Net Income	-$359.64M	-$22.78M	$3.51B	$390.55M
7 Day Performance	8.87%	-2.85%	-1.49%	-0.33%
1 Month Performance	14.72%	-3.75%	-2.55%	-4.82%
1 Year Performance	-25.29%	-1.56%	0.92%	-5.83%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	3.5997 of 5 stars	$29.22 +5.9%	$93.36 +219.5%	-25.1%	$3.52B	N/A	N/A	74	Options Volume High Trading Volume
MDGL Madrigal Pharmaceuticals	4.2524 of 5 stars	$433.03 +0.1%	$706.87 +63.2%	-17.0%	$10.05B	$958.40M	N/A	915	Analyst Forecast
LLY Eli Lilly and Company	3.8473 of 5 stars	$1,437.46 +0.4%	$1,416.64 -1.4%	+41.3%	$1.35T	$65.18B	46.66	50,000	Trending News Analyst Downgrade
PFE Pfizer	2.805 of 5 stars	$29.42 +0.2%	$30.39 +3.3%	+12.0%	$167.35B	$62.58B	9.63	75,000	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.0769 of 5 stars	$16.64 -6.7%	$28.61 +71.9%	-22.5%	$14.26B	N/A	N/A	265

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, SMMT, and HALO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Summary

How does Viking Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, SMMT, and HALO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Which has more risk & volatility, MDGL or VKTX?

Which has better earnings and valuation, MDGL or VKTX?

Does the media favor MDGL or VKTX?

Do institutionals and insiders believe in MDGL or VKTX?

Is MDGL or VKTX more profitable?

Do analysts recommend MDGL or VKTX?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Which has more volatility & risk, LLY or VKTX?

Do institutionals & insiders believe in LLY or VKTX?

Is LLY or VKTX more profitable?

Which has higher earnings & valuation, LLY or VKTX?

Does the media favor LLY or VKTX?

Do analysts prefer LLY or VKTX?

Summary

How does Viking Therapeutics compare to Pfizer?

Is VKTX or PFE more profitable?

Do analysts prefer VKTX or PFE?

Which has more risk and volatility, VKTX or PFE?

Does the media prefer VKTX or PFE?

Do insiders & institutionals have more ownership in VKTX or PFE?

Which has better valuation & earnings, VKTX or PFE?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Does the media prefer SMMT or VKTX?

Which has higher valuation and earnings, SMMT or VKTX?

Do analysts prefer SMMT or VKTX?

Which has more risk & volatility, SMMT or VKTX?

Is SMMT or VKTX more profitable?

Do institutionals and insiders have more ownership in SMMT or VKTX?

Summary

How does Viking Therapeutics compare to Halozyme Therapeutics?

Do insiders and institutionals hold more shares of VKTX or HALO?

Which has more volatility & risk, VKTX or HALO?

Which has better earnings & valuation, VKTX or HALO?

Is VKTX or HALO more profitable?

Does the media refer more to VKTX or HALO?

Do analysts prefer VKTX or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools